How PAMA Reimbursement Will Change and Impact Lab Customers

Log in to view the webinar or take the test.

For the second year in a row, Congress acted to suspend scheduled Medicare cuts in order to provide financial relief to hospitals and providers amid the COVID-19 Public Health Emergency. This included the next round of Protecting Access to Medicare Act (PAMA) data reporting and associated Clinical Lab Fee Schedule (CLFS) cuts to be delayed one year until 2023. Without the delay, many tests were set to see cuts of up to 15% of 2021 rates. In this session, you’ll learn:

• How lab providers get paid, and how that’s has been changing
• What you can be doing now to be ready for  2023 PAMA reimbursement cuts
• Other reimbursement changes that will impact the lab market that are on the horizon